caa a22 4500 445336692 CHVBK 20180317142758.0 cr unu---uuuuu 170323e20110501xx s 000 0 eng 10.1245/s10434-010-1448-7 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1448-7 Influence of A9 Region Mutation in EphB2 Gene in the Prognosis of Patients with Colorectal Adenocarcinoma [Elektronische Daten] [M. Vidaurreta, S. Rafael, S. Veganzones, V. de la Orden, C. Fernández, R. Gómez-Casaseca, J. Cerdán, M. Maestro] Background: EphB2 is a transmembrane glycoprotein implicated in the regulation of cell growth, differentiation, and motility. It has been proposed as a tumor suppressor gene, and the role of EphB2 protein in tumorogenesis has been demonstrated. The aim of this study was to test the influence of mutation of A9 region in EphB2 gene in the prognosis of patients with sporadic CCR. Materials and Methods: A total of 473 patients with colorectal cancer were included. A9 region in exon 17 of EphB2 was amplified using specific primer and analyzed using Genescan. All mutations were confirmed by direct sequencing. Results: EphB2 mutation was detected in 13 of the 473 patients (2.7%). Mutation of EphB2 showed association with tumor site, 12 of 13 mutations were proximal tumors (P<0.001). EphB2 mutation confers better prognosis in the adenocarcinoma group; 100% of patients carrying the mutation survived and were disease free after 72months (P=0.02 and 0.03, respectively). Conclusions: Despite the low frequency of EphB2 gene, we got promising results. It would be very interesting to increase the population size to verify our results. If these findings are confirmed, EphB2 could help discriminate patients with adenocarcinoma with different prognosis and to improve the election of the most suitable treatment in each case. Society of Surgical Oncology, 2010 Vidaurreta M. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut Rafael S. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut Veganzones S. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut de la Orden V. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut Fernández C. Investigation Unit, Hospital Clínico San Carlos, Madrid, Spain aut Gómez-Casaseca R. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut Cerdán J. Department of General Surgery III, Hospital Clínico San Carlos, Madrid, Spain aut Maestro M. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut Annals of Surgical Oncology Springer-Verlag 18/5(2011-05-01), 1501-1505 1068-9265 18:5<1501 2011 18 10434 https://doi.org/10.1245/s10434-010-1448-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1448-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Vidaurreta M. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut NATIONALLICENCE 700 1- Rafael S. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut NATIONALLICENCE 700 1- Veganzones S. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut NATIONALLICENCE 700 1- de la Orden V. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut NATIONALLICENCE 700 1- Fernández C. Investigation Unit, Hospital Clínico San Carlos, Madrid, Spain aut NATIONALLICENCE 700 1- Gómez-Casaseca R. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut NATIONALLICENCE 700 1- Cerdán J. Department of General Surgery III, Hospital Clínico San Carlos, Madrid, Spain aut NATIONALLICENCE 700 1- Maestro M. Department of Clinical Analysis, Hospital Clínico San Carlos, Madrid, Spain aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/5(2011-05-01), 1501-1505 1068-9265 18:5<1501 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer